The Scripps Research Institute has disclosed peptides and their drug conjugates acting as dual gastric inhibitory polypeptide receptor (GIPR) and glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes, metabolic dysfunction-associated steatotic liver disease and obesity.